LOADING
Comparing JPMorgan Chase (JPM) and Merck & Company (MRK) across the Financials and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JPM | MRK |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $934.5B | $367.6B |
| P/E Ratio | 15.3 | 122.1 |
| Forward P/E | 15.0 | 55.3 |
| PEG Ratio | 1.75 | 14.56 |
| EPS | $22.96 | $1.22 |
| Revenue Growth (YoY) | 30.4% | 5.1% |
| Profit Margin | 34.9% | 4.8% |
| Return on Equity | 17.8% | 7.0% |
| Dividend Yield | 1.68% | 2.18% |
| Beta | 0.98 | 0.21 |
| 52-Week High | $366.50 | $153.50 |
| 52-Week Low | $276.44 | $75.81 |
| Volume | -- | -- |
JPMorgan Chase is the larger company by market capitalization. JPMorgan Chase trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. JPMorgan Chase has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.